These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 36601687)

  • 1. Modulating tumour vascular normalisation using triptolide-loaded NGR-functionalized liposomes for enhanced cancer radiotherapy.
    Xu YY; Chen YH; Jin J; Yuan Y; Li JM; Cai XJ; Zhang RY
    J Liposome Res; 2023 Sep; 33(3):251-257. PubMed ID: 36601687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of metronomic administration and target delivery strategies to improve the anti-angiogenic and anti-tumor effects of triptolide.
    Cai XJ; Fei WD; Xu YY; Xu H; Yang GY; Cao JW; Ni JJ; Wang Z
    Drug Deliv Transl Res; 2020 Feb; 10(1):93-107. PubMed ID: 31418132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal-targeted delivery of triptolide by entrapment in pegylated TRX-20-modified liposomes.
    Yuan ZX; Jia L; Lim LY; Lin JC; Shu G; Zhao L; Ye G; Liang XX; Ji H; Fu HL
    Int J Nanomedicine; 2017; 12():5673-5686. PubMed ID: 28848346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NGR-modified pH-sensitive liposomes for controlled release and tumor target delivery of docetaxel.
    Gu Z; Chang M; Fan Y; Shi Y; Lin G
    Colloids Surf B Biointerfaces; 2017 Dec; 160():395-405. PubMed ID: 28965079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triptolide-nanoliposome-APRPG, a novel sustained-release drug delivery system targeting vascular endothelial cells, enhances the inhibitory effects of triptolide on laser-induced choroidal neovascularization.
    Lai K; Li Y; Gong Y; Li L; Huang C; Xu F; Zhong X; Jin C
    Biomed Pharmacother; 2020 Nov; 131():110737. PubMed ID: 32932044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced small interfering RNA delivery into cells by exploiting the additive effect between photo-sensitive peptides and targeting ligands.
    Lin W; Xie X; Yang Y; Liu H; Fu X; Chen Y; Liu H; Yang Y
    J Pharm Pharmacol; 2015 Sep; 67(9):1215-31. PubMed ID: 25880614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
    Pastorino F; Brignole C; Marimpietri D; Cilli M; Gambini C; Ribatti D; Longhi R; Allen TM; Corti A; Ponzoni M
    Cancer Res; 2003 Nov; 63(21):7400-9. PubMed ID: 14612539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A photo-responsive peptide- and asparagine-glycine-arginine (NGR) peptide-mediated liposomal delivery system.
    Xie X; Yang Y; Yang Y; Zhang H; Li Y; Mei X
    Drug Deliv; 2016 Sep; 23(7):2445-2456. PubMed ID: 25693640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The antiangiogenic efficacy of NGR-modified PEG-DSPE micelles containing paclitaxel (NGR-M-PTX) for the treatment of glioma in rats.
    Zhao BJ; Ke XY; Huang Y; Chen XM; Zhao X; Zhao BX; Lu WL; Lou JN; Zhang X; Zhang Q
    J Drug Target; 2011 Jun; 19(5):382-90. PubMed ID: 20677914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. pH-Sensitive PEGylated Liposomal Silybin: Synthesis, In Vitro and In Vivo Anti-Tumor Evaluation.
    Gheybi F; Alavizadeh SH; Rezayat SM; Hatamipour M; Akhtari J; Faridi Majidi R; Badiee A; Jaafari MR
    J Pharm Sci; 2021 Dec; 110(12):3919-3928. PubMed ID: 34418455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular infarction by subcutaneous application of tissue factor targeted to tumor vessels with NGR-peptides: activity and toxicity profile.
    Dreischalück J; Schwöppe C; Spieker T; Kessler T; Tiemann K; Liersch R; Schliemann C; Kreuter M; Kolkmeyer A; Hintelmann H; Mesters RM; Berdel WE
    Int J Oncol; 2010 Dec; 37(6):1389-97. PubMed ID: 21042706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel gemcitabine derivative-loaded liposome with great pancreas-targeting ability.
    Li PW; Luo S; Xiao LY; Tian BL; Wang L; Zhang ZR; Zeng YC
    Acta Pharmacol Sin; 2019 Nov; 40(11):1448-1456. PubMed ID: 31015736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. APN/CD13-targeting as a strategy to alter the tumor accumulation of liposomes.
    Dunne M; Zheng J; Rosenblat J; Jaffray DA; Allen C
    J Control Release; 2011 Sep; 154(3):298-305. PubMed ID: 21640146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo evaluation of novel NGR-modified liposomes containing brucine.
    Li S; Wang XP
    Int J Nanomedicine; 2017; 12():5797-5804. PubMed ID: 28860749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid composition has significant effect on targeted drug delivery properties of NGR-modified liposomes.
    Chen J; Lin A; Peng P; Wang Y; Gu W; Liu Y
    Drug Deliv; 2016 May; 23(4):1426-33. PubMed ID: 26373704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-targeting NGR-modified liposomes recognizing glioma tumor cells and vasculogenic mimicry for improving anti-glioma therapy.
    Huang D; Zhang S; Zhong T; Ren W; Yao X; Guo Y; Duan XC; Yin YF; Zhang SS; Zhang X
    Oncotarget; 2016 Jul; 7(28):43616-43628. PubMed ID: 27283987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NGR-TNF, a novel vascular-targeting agent, does not induce cytokine recruitment of proangiogenic bone marrow-derived cells.
    Di Matteo P; Hackl C; Jedeszko C; Valentinis B; Bordignon C; Traversari C; Kerbel RS; Rizzardi GP
    Br J Cancer; 2013 Jul; 109(2):360-9. PubMed ID: 23828516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel drug delivery liposomes targeted with a fully human anti-VEGF165 monoclonal antibody show superior antitumor efficacy in vivo.
    Shi C; Cao H; He W; Gao F; Liu Y; Yin L
    Biomed Pharmacother; 2015 Jul; 73():48-57. PubMed ID: 26211582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nano drug delivery system reconstruct tumour vasculature for the tumour vascular normalisation.
    Liang Q; Zhou L; Li Y; Liu J; Liu Y
    J Drug Target; 2022 Feb; 30(2):119-130. PubMed ID: 33960252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma.
    Zuccari G; Milelli A; Pastorino F; Loi M; Petretto A; Parise A; Marchetti C; Minarini A; Cilli M; Emionite L; Di Paolo D; Brignole C; Piaggio F; Perri P; Tumiatti V; Pistoia V; Pagnan G; Ponzoni M
    J Control Release; 2015 Aug; 211():44-52. PubMed ID: 26031842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.